{"id":573231,"date":"2025-12-19T00:00:00","date_gmt":"2025-12-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0002-2025-biopharma-colorectal-cancer-disease-landscape-and-forecast-g7-2025\/"},"modified":"2026-04-30T11:10:11","modified_gmt":"2026-04-30T11:10:11","slug":"dlsfon0002-2025-biopharma-colorectal-cancer-disease-landscape-and-forecast-g7-2025","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0002-2025-biopharma-colorectal-cancer-disease-landscape-and-forecast-g7-2025\/","title":{"rendered":"Colorectal Cancer | Disease Landscape and Forecast | G7 | 2025"},"content":{"rendered":"<p>Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without <em>RAS<\/em> mutations also benefit from EGFR inhibitors (Merck &#038; Co. \/ Eli Lilly\u2019s Erbitux and Amgen\u2019s Vectibix), which are recommended for first-line treatment of patients with left-sided tumors. Additional targeted therapies for specific molecular subtypes have been developed: immune checkpoint inhibitors (Merck &#038; Co.\u2019s Keytruda and Bristol Myers Squibb\u2019s Opdivo and Yervoy) for MSI-high and\/or MMR-deficient tumors, BRAF inhibitors (Array BioPharma \/ Pfizer\u2019s Braftovi) for <em>BRAF V600E<\/em>-mutated tumors, KRAS inhibitors (Bristol Myers Squibb\u2019s Krazati and Amgen\u00b4s Lumakras) for <em>KRAS G12C<\/em>-mutated tumors and HER2-targeted agents, (Chugai\u2019s Perjeta and trastuzumab and Seagen\u2019s Tukysa) available in some markets for HER2-positive metastatic disease. Therapies in late-phase development aim to address additional genomic alterations, such as c-MET overexpression, expand the pool of KRAS inhibitors for <em>KRAS G12C<\/em>-mutated tumors and anti-EGFR-targeted therapies for left- and right-sided <em>RAS\/BRAF <\/em>wild-type tumors, and evaluate novel immunotherapy-based approaches for treating MSS and\/or pMMR tumors.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>How large are the drug-treatable colorectal cancer populations?<\/li>\n<li>How do patient populations differ by disease stage and key biomarkers?<\/li>\n<li>What are interviewed experts\u2019 views on current and emerging late-phase therapies?<\/li>\n<\/ul>\n<p><strong>Geography: <\/strong>United States, EU5, Japan.<\/p>\n<p><strong>Primary research:\u00a0<\/strong>Country-specific interviews with thought-leading medical oncologists; survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed and recurrent incidence of colorectal cancer; drug-treatable and -treated cases by country, disease stage, tumor side, BRAF status, and RAS status.<\/p>\n<p><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key colorectal cancer therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations.<\/p>\n<p><strong>Drug treatments: <\/strong>Coverage of key current and emerging therapies.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul>\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-573231","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-colorectal-cancer","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573231","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573231\/revisions"}],"predecessor-version":[{"id":575241,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573231\/revisions\/575241"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=573231"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}